Various clinical presentations of uveitis associated with durvalumab treatment

• Published in: Radiology and oncology 2022-04, Vol.56 (2), p.129-137
• Main Authors: Vrabic, Nika, Fakin, Ana, Mekjavic, Polona Jaki, Janzic, Urska, Vrankar, Martina, Valentincic, Natasa Vidovic
• Format: Article
• Language: English
• Subjects: adverse effects; Antibodies, Monoclonal - adverse effects; CD80 antigen; durvalumab; Edema; Humans; immune checkpoint inhibitor; Immune Checkpoint Inhibitors; Immunoglobulin G; Immunotherapy; Inhibitors; Literature reviews; Lung cancer; Lung Neoplasms - drug therapy; Monoclonal antibodies; Non-small cell lung carcinoma; optic disc oedema; Papilledema - drug therapy; PD-1 protein; PD-L1 protein; Review; Small cell lung carcinoma; Targeted cancer therapy; Uveitis; Uveitis - drug therapy; Uveitis, Posterior - drug therapy; Vasculitis
• ISSN: 1581-3207; 1318-2099; 1581-3207; 0485-893X
• DOI: 10.2478/raon-2022-0007

Immune checkpoint inhibitors (ICI) are becoming increasingly common in treating several cancer types. Durvalumab is a human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 and has recently been approved for the treatment of extensive-stage small-cell lung cancer (ES-SCLC) and locally advanced unresectable (NSCLC). The present review aimed to analyse immune-mediated uveitis, secondary to durvalumab treatment, through a review of the literature and a presentation of two clinical cases. A literature review using PubMed search was conducted to identify cases of uveitis secondary to durvalumab and cases of uveitis with optic disc oedema secondary to ICI use that were reported prior to November 14, 2021. Additionally, we report two cases of uveitis consequent on durvalumab treatment. Five cases of uveitis secondary to durvalumab use were identified in the literature. Anterior, posterior uveitis and vasculitis were reported. Additionally, we present a case of bilateral intermediate uveitis with bilateral optic disc oedema and a case of bilateral posterior uveitis. Our further search revealed 12 cases of uveitis with optic disc oedema secondary to ICI use, with the majority of cases reported secondary to PD-1 inhibitors. Rarely reported, uveitis secondary to durvalumab can present various clinical pictures and requires a thorough diagnostic workup. Once the diagnosis is established, treatment, commonly with a local or systemic corticosteroid, should be adapted to the severity of the inflammation.